YK Bioventures

Activity from announced rounds

All recorded activity

YK Bioventures is the life-sciences venture firm whose own profile identifies Think Bio, Vivere, Moonwalk and Tempo.

Recorded funding activity

Think develops small-molecule medicines. Moonwalk targets fat-tissue pathways, while Tempo develops regenerative scaffolds. These programs pursue distinct therapeutic mechanisms within the recorded activity.

Sources
Rounds participated in
5
Confirmed lead rounds
1
2 roles undisclosed
New companies
5
First participation on record · 0 follow-on
Funding in participating rounds
$249.5M
5 disclosed · full round size, not this investor’s share

By stage

Series A2
Series B1
Series C+1
Undisclosed1

By primary sector

Biotech5

By country

United States5

Rounds

5 in all activity
Delix Therapeutics

Delix Therapeutics develops neuroplastogen medicines for psychiatric and neurological disorders.

$100MSeries C
Participant
Tempo Therapeutics

A regenerative-medicine company developing injectable microporous scaffolds that help the body rebuild tissue at damaged sites.

$14.5MFunding
Participant
Moonwalk Biosciences

Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027.

$70MSeries B
Lead
Think Bioscience

Develops small molecule drugs for historically challenging drug targets

$55MSeries A
Role not disclosed
Vivere Oncotherapies

Vivere Oncotherapies develops cancer treatments designed to activate immune recognition and destruction of cancer cells.

$10MSeries A
Role not disclosed